|
Seminar luncheon
Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
Speakers:
John Sninsky, PhD, CSO-CIO of Molecular Stethoscope
Organizers:
Date:
2024-06-20
Time:
11:00-14:30 Pacific Time
Registration fee:
Vendor Show: $695; Regular attendees:: Free
Location:
Crowne Plaza, Foster City, CA (San Francisco Bay Area)
Major Sponsor:
Vendor show vendors registered to date:
(2)Agilent Technologies; HICOMP MicroTech Co. Ltd
Registration: http://www.PBSS.org
Registration deadline:2024-06-19
(it will close sooner if the seating cap is reached)
About the Topic
Vendor Show registration is open
Regular attendees' registration will open on May 20th, 2024 About the SpeakersJohn J Sninsky, PhD, is CSO-CIO for Superfluid Dx, an early-stage biotechnology company with a disease agnostic pioneering cell free mRNA platform that uses NGS and machine learning to develop classifiers for compelling unmet clinical needs. Superfluid Dx has prioritized Alzheimer’s Disease. John has a comprehensive and deep understanding of the development and application of pioneering molecular procedures and bioinformatics to the translation of research-grade biomarker assays into clinical-grade clinically adopted diagnostic tests as well as diagnostic tests paired with pharmacotherapies. John is the author of more than 115 scientific papers including advanced methods in molecular biology and next generation sequencing. He spent 30 years in senior management at companies that ranged from small to enterprise CLIA-CAP laboratories and small to enterprise in vitro diagnostic companies that required FDA clearance and approval for commercialization of kits. He lectures at and advises commercial translation efforts at Stanford University (SPARK) and University of California, San Francisco (CATALYST). John is a Visiting Professor in the Division Infectious Diseases and Vaccinology in School of Public Health at UC Berkeley. He mentors Biomedical Data Science projects for the Data Mine at Purdue University.
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
Lena Biosciences
Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
|
Hypha Discovery
Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
|
Lena Biosciences
Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Submit a Text Ad
|